The biotechnology company said in a statement on Monday that an interim analysis showed a robust neutralizing antibody response in children 6 to under 12 years old. Participants in the trial received two 50 microgram doses—half the dose initially given to adults—spaced 28 days apart.

The trial data also showed a favorable safety profile, the company said. 

Moderna said that it planes to submit the data to the Food and Drug Administration, as well as the European Medicines Agency and other global regulators, in the near term.

Shares of Moderna gained 0.8% in premarket trading in New York on Monday. The stock had been under pressure of late, sliding by about 24% over the past month.

The release of data from Moderna comes a day before an FDA panel is expected to review data on the COVID-19 vaccine for 5- to 11-year-olds from Pfizer Inc. and BioNTech SE. 

More health care and Big Pharma coverage from Fortune:

• What you need to know about the Delta Plus COVID variant and the danger it poses
• Should kids under 12 get the COVID vaccine? What parents should know
• Intrivo launches new at-home rapid test for COVID amid U.S. supply shortage
• COVID-19 vaccine makers could inoculate the world by the end of 2022, says J&J CEO Alex Gorsky
• Got the J&J vaccine? Here’s what you need to know about boosters